Introduction:
Obesity and overweight characterize many patients with acute coronary syndrome (ACS). In the ODYSSEY OUTCOMES trial, alirocumab reduced major adverse cardiovascular events (MACE) post-ACS compared with placebo, with protocol-driven dose up-titration from 75 to 150 mg to achieve target LDL-cholesterol (...
G. Schwartz, H. Tavori, Xin Zheng et al.· Circulation· 0 citations
Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...
M. Szarek, D. L. Bhatt, M. Miller et al.· European Heart Journal· 0 citations
The conclusion that residual risk in ACS is multidimensional is supported, and comprehensive biomarker profiling with a multiplex apolipoprotein panel including apoE phenotypes and emerging CKM tests each provides clinically meaningful improvement in the prediction of MACE and death beyond conventional demographics, di...
N. V. van Neer, J. Jukema, L. Ruhaak et al.· Circulation· 0 citations
Patients with heterozygous familial hypercholesterolaemia (HeFH), if untreated or undertreated, are characterised by lifelong exposure to elevated low density lipoprotein cholesterol (LDLc) levels, associated with a markedly increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent surveys, however...
E. Stroes, R. S. Rosenson, R. Santos et al.· European Heart Journal· 0 citations
AIMS
New-onset diabetes (NoD) is a recognised effect of statin therapy potentially influencing acceptance of intensive LDL-C-lowering. In contrast, cholesteryl ester transfer protein (CETP) inhibition has been associated with lower NoD risk in earlier trials. We assessed the effect of the highly selective CETP inhibito...
J. Brandts, M. Szarek, S. J. Nicholls et al.· European Journal of Preventi...· 0 citations
Cholesteryl ester transfer protein (CETP), required for transferring triglyceride from very-low-density lipoprotein in exchange for cholesteryl ester from high-density lipoprotein (HDL), is also involved in lipophilic antioxidant exchange. We aimed to determine the effects of the next generation potent CETP inhibitor...
Eric J. Niesor, M. Ditmarsch, Serge Rezzi et al.· Scientific Reports· 1 citation
Findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.
M. Szarek, Deepak L. Bhatt, Michael Miller et al.· Journal of Clinical Lipidolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.